Treatment of steroid-sensitive nephrotic syndrome: new guidelines from KDIGO

Pediatr Nephrol. 2013 Mar;28(3):415-26. doi: 10.1007/s00467-012-2310-x. Epub 2012 Oct 3.

Abstract

The 2012 Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guideline on glomerulonephritis (GN) is intended to assist the practitioner caring for patients with GN. Two chapters of this guideline focus specifically on nephrotic syndrome in children. Guideline development followed a thorough evidence review, and management recommendations and suggestions were based on the best available evidence. Critical appraisal of the quality of evidence and strength of recommendations followed the Grades of Recommendation Assessment, Development and Evaluation (GRADE) approach. Chapters 3 and 4 of the guideline focus on the management of nephrotic syndrome in children aged 1-18 years. Guideline recommendations for children who have steroid-sensitive nephrotic syndrome (SNSS), defined by their response to corticosteroid therapy with complete remission, are addressed here. Recommendations for those with steroid-resistant nephrotic syndrome (SRNS) (i.e., do not achieve complete remission) are discussed in the companion article. Limitations of the evidence, including the paucity of large-scale randomized controlled trials, are discussed. This article provides a short description of the KDIGO process, the guideline recommendations for treatment of SSNS in children and a brief review of relevant treatment trials related to each recommendation.

Publication types

  • Practice Guideline
  • Review

MeSH terms

  • Adolescent
  • Adrenal Cortex Hormones / therapeutic use*
  • Child
  • Child, Preschool
  • Consensus
  • Evidence-Based Medicine / standards
  • Humans
  • Infant
  • Nephrology / standards*
  • Nephrotic Syndrome / diagnosis
  • Nephrotic Syndrome / drug therapy*
  • Remission Induction
  • Treatment Outcome

Substances

  • Adrenal Cortex Hormones

Supplementary concepts

  • Nephrosis, congenital